Melissa Rijken

596 total citations · 1 hit paper
13 papers, 326 citations indexed

About

Melissa Rijken is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Melissa Rijken has authored 13 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 7 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Melissa Rijken's work include Acute Myeloid Leukemia Research (12 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Cancer Genomics and Diagnostics (3 papers). Melissa Rijken is often cited by papers focused on Acute Myeloid Leukemia Research (12 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Cancer Genomics and Diagnostics (3 papers). Melissa Rijken collaborates with scholars based in Netherlands, Switzerland and Belgium. Melissa Rijken's co-authors include Peter J.M. Valk, Bob Löwenberg, Mathijs A. Sanders, Mojca Jongen‐Lavrencic, Tim Grob, François G. Kavelaars, Adil S. A. Al Hinai, Gert J. Ossenkoppele, Marinus van Marwijk Kooy and Patrycja Gradowska and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Melissa Rijken

13 papers receiving 324 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

2022 159 citations Tim Grob, Adil S. A. Al Hinai et al. Blood profile →

Peers

Countries citing papers authored by Melissa Rijken

Since Specialization

Citations

This map shows the geographic impact of Melissa Rijken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Rijken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Rijken more than expected).

Fields of papers citing papers by Melissa Rijken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Rijken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Rijken. The network helps show where Melissa Rijken may publish in the future.

Co-authorship network of co-authors of Melissa Rijken

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Rijken. A scholar is included among the top collaborators of Melissa Rijken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Rijken. Melissa Rijken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia 2025 ·Blood Advances ·(unknown), (unknown), François G. Kavelaars, (unknown), Sofia Nordin, (unknown), Melissa Rijken, (unknown), Jurjen Versluis, Bob Löwenberg, Peter J.M. Valk	2
2	Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML 2024 ·Blood Advances ·(unknown), Tim Grob, Melissa Rijken, François G. Kavelaars, (unknown), Gert J. Ossenkoppele, Markus G. Manz, (unknown), (unknown), Bob Löwenberg, Peter J.M. Valk	2
3	Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA 2024 ·HemaSphere ·(unknown), (unknown), François G. Kavelaars, Melissa Rijken, (unknown), (unknown), Bob Löwenberg, Tim Grob, Peter J.M. Valk	1
4	Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis 2024 ·Blood Advances ·(unknown), (unknown), Annelieke Zeilemaker, (unknown), Melissa Rijken, François G. Kavelaars, Tim Grob, Jurjen Versluis, Bob Löwenberg, Peter J.M. Valk, Mathijs A. Sanders	2
5	High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL 2023 ·HemaSphere ·Paul J. Hengeveld, (unknown), Jeroen Demmers, (unknown), Julie Dubois, Melissa Rijken, (unknown), (unknown), (unknown), (unknown), Peter J.M. Valk, Laura M. Faber, Peter E. Westerweel, Arnon P. Kater, Mark‐David Levin, Anton W. Langerak	3
6	Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome breakdown → 2022 ·Blood ·Tim Grob, Adil S. A. Al Hinai, Mathijs A. Sanders, François G. Kavelaars, Melissa Rijken, Patrycja Gradowska, Bart J. Biemond, Dimitri Breems, Johan Maertens, Marinus van Marwijk Kooy, Thomas Pabst, Okke de Weerdt, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Gerwin Huls, Jan J. Cornelissen, H. Berna Beverloo, Bob Löwenberg, Mojca Jongen‐Lavrencic, Peter J.M. Valk	159
7	Poster: AML-234 Prognostic Value of FLT3-ITD Residual Disease in Acute Myeloid Leukemia 2022 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Tim Grob, Mathijs A. Sanders, François G. Kavelaars, Melissa Rijken, Diana Hanekamp, Patrycja Gradowska, (unknown), (unknown), Marinus van Marwijk Kooy, Markus G. Manz, Gert J. Ossenkoppele, Lidwine W. Tick, Marie‐Christiane Vekemans, Bob Löwenberg, Mojca Jongen‐Lavrencic, Peter J.M. Valk	1
8	Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia 2022 ·Journal of Clinical Oncology ·Tim Grob, Mathijs A. Sanders, (unknown), (unknown), Melissa Rijken, Diana Hanekamp, Patrycja Gradowska, Jacqueline Cloos, Yngvar Fløisand, Marinus van Marwijk Kooy, Markus G. Manz, Gert J. Ossenkoppele, Lidwine W. Tick, Violaine Havelange, Bob Löwenberg, Mojca Jongen‐Lavrencic, Peter J.M. Valk	69
9	AML-234 Prognostic Value of FLT3-ITD Residual Disease in Acute Myeloid Leukemia 2022 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Tim Grob, Mathijs A. Sanders, François G. Kavelaars, Melissa Rijken, Diana Hanekamp, Patrycja Gradowska, (unknown), (unknown), Marinus van Marwijk Kooy, Markus G. Manz, Gert J. Ossenkoppele, Lidwine W. Tick, Marie‐Christiane Vekemans, Bob Löwenberg, Mojca Jongen‐Lavrencic, Peter J.M. Valk	1
10	PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse 2021 ·Leukemia ·Adil S. A. Al Hinai, Tim Grob, Melissa Rijken, François G. Kavelaars, Annelieke Zeilemaker, Claudia Erpelinck-Verschueren, Mathijs A. Sanders, Bob Löwenberg, Mojca Jongen‐Lavrencic, Peter J.M. Valk	6
11	DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia 2021 ·Blood Advances ·(unknown), (unknown), Melissa Rijken, François G. Kavelaars, (unknown), (unknown), (unknown), Zinia J. Kwidama, Patrycja Gradowska, Bob Löwenberg, Jeroen J. W. M. Janssen, Jacqueline Cloos, Peter J.M. Valk	3
12	MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML 2018 ·Blood ·Mathijs A. Sanders, Edward Chew, Christoffer Flensburg, Annelieke Zeilemaker, Sarah E. Miller, Adil S. A. Al Hinai, Ashish Bajel, (unknown), Melissa Rijken, (unknown), Remco M. Hoogenboezem, François G. Kavelaars, Stefan Fröhling, Marnie E. Blewitt, Eric M. Bindels, Warren S. Alexander, Bob Löwenberg, Andrew W. Roberts, Peter J.M. Valk, Ian J. Majewski	76
13	DNMT3A Mutations Enhance CpG Mutagenesis through Deregulation of the Active DNA Demethylation Pathway 2016 ·Blood ·Mathijs A. Sanders, Annelieke Zeilemaker, Adil Al Hinai, Remco M. Hoogenboezem, François G. Kavelaars, Melissa Rijken, Eric M. Bindels, Bob Löwenberg, Peter J.M. Valk	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact